Jen Gunter, MD, obstetrician and gynecologist, author, and specialist in chronic pain medicine and vulvovaginal disorders, spoke on the change in perspective regarding the medical and scientific community's role in dispelling health care misinformation on social media and in the press.
Jennifer Green, MD, professor of medicine at Duke University School of Medicine, member of Duke Clinical Research Institute, and EMPA-KIDNEY collaborator, discussed findings of the EMPA-KIDNEY trial presented at Kidney Week 2022, which showed a 28% improvement for patients with chronic kidney disease (CKD) on empagliflozin, whether in reduced mortality from cardiovascular disease or progression of CKD.
With no sign that medical misinformation is going away, a session at Kidney Week 2022 delved into how nephrologists and researchers can educate and inform the public.
Access to care remains a key issue when trying to deliver equitable kidney health care to patients, explained O.N. Ray Bignall II, MD, assistant chief diversity and health equity officer at Nationwide Children’s Hospital.
Brent W. Miller, MD, board certified nephrologist and professor of clinical medicine at Indiana University School of Medicine, discussed new and emerging technologies for at-home hemodialysis and peritoneal dialysis, as well as efforts that have been made to address uptake issues for patients with kidney disease.
Ahead of the big wave of adalimumab biosimilars launching in the US market in 2023, rheumatologists report growing confidence in using biosimilars but remain concerned about their efficacy and economic benefit.
Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of Dermatology at the University of California Davis in Sacramento, spoke on challenges in the management of hidradenitis suppurativa (HS), as well as promising therapies in the pipeline that target specific pathways suggested to play a role in the pathogenesis and pathophysiology of the disease.
Two data sets from patients with severe pulmonary arterial hypertension (PAH) show the benefits of macitentan (Opsumit) monotherapy despite guidelines calling for combination therapy, even among patients with World Health Organizational functional class I-II disease.
The 2023 Physician Fee Schedule final rule was released and swiftly drew condemnations from physician leaders because of a 4.5% cut to reimbursement.
The findings suggest telenursing between in-person visits may help reduce distress related to symptoms in patients who have lung cancer.
Emergency department (ED) readmission was more common than dermatology follow-up among patients with hidradenitis suppurativa (HS) within 30 and 180 days of initially presenting to the ED, with patients with Medicaid coverage and those who had an opioid prescribed were more likely to return.
Susan E. Quaggin, MD, FASN, president of the American Society of Nephrology (ASN) for the 2021-2022 term, discussed the major focuses and breakthroughs in nephrology to be presented at Kidney Week 2022, which include novel treatments for common and rare kidney diseases, as well as efforts to address disparities for transplant and care access.
A significant uptick in chronic rhinosinusitis with nasal polyps (CRSwNP) among patients with comorbid asthma has been seen in the country over the past decade.
Brian Corvino, MBA, managing director, Life Sciences and Health Care Practice, Deloitte Consulting, LLP, offered an overview of how the surge of innovation in oncology—and resulting drug approvals—dominate the biopharmaceutical sector. He spoke at the Community Oncology Alliance's Payer Exchange Summit.
Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope in Duarte, California, discusses the recently passed Cancer Care Equity Act in California that provides access to clinical trials and advanced care for Medi-Cal beneficiaries.
The quest to deliver better cancer care—with better outcomes and patient experience—is not a one-size-fits-all journey, as seen in panels during the Community Oncology Alliance (COA) Payer Exchange Summit, held in Tyson’s Corner, Virginia.
Having a plan in place to educate providers and the pharmacy team has contributed to the success that Rocky Mountain Cancer Centers (RMCC) has had with rapidly implementing biosimilars, said Timothy Murphy, MD, medical oncologist/hematologist with RMCC.
Patients with young-onset Parkinson disease experience significant emotional burden that is exacerbated by unmet educational needs.
It is unclear what role treatment plays in affecting hepatocellular carcinoma (HCC) risk, the authors found.
In an interview, the section chief of hepatology at Rush University Medical Center discussed why the addition of the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis code K76.82 is necessary.
The FDA’s approval of teclistamab for relapsed/refractory (R/R) multiple myeloma makes it the first bispecific T-cell engager antibody to enter the treatment landscape.
Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, discussed how prior authorizations and other insurance requirements are limiting treatment access in atopic dermatitis and how dermatologists can help ameliorate these approval issues.
Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected with hidradenitis suppurativa (HS), spoke on common stigmas regarding HS and how clinicians can improve consultation through a culturally sensitive approach.
A systematic review found that changes in neural mechanisms as a result of ketamine treatment could play a role in treatment outcomes of ketamine-assisted psychotherapy.
Improved outcomes associated with fidaxomicin compared with vancomycin suggest benefits from its greater use in Medicare patients, although uptake remains low despite its recommended use.
